These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21497638)

  • 21. Meningococcal serogroup C polysaccharide specific memory B cells, directly enumerated by labeled polysaccharide, are not affected by age at vaccination.
    Henneken M; Burdin N; Thoroddsen E; Sigurdardottir ST; Trannoy E; Jonsdottir I
    Vaccine; 2010 Feb; 28(9):2097-103. PubMed ID: 20056181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.
    Mountzouros KT; Belanger KA; Howell AP; Bixler GS; Madore DV
    Infect Immun; 2002 Dec; 70(12):6576-82. PubMed ID: 12438327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.
    Borrow R; Goldblatt D; Andrews N; Richmond P; Southern J; Miller E
    J Infect Dis; 2001 Aug; 184(3):377-80. PubMed ID: 11443568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines.
    Wysocki J; Tansey S; Brachet E; Baker S; Gruber W; Giardina P; Arora A
    Vaccine; 2010 Nov; 28(49):7779-86. PubMed ID: 20883736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of serum bactericidal antibody and opsonic antibody levels after Neisseria meningitidis serogroup C conjugate vaccine in Brazilian children and adolescents infected or not infected with HIV.
    Pereira-Manfro WF; Alvino RM; Cruz AC; Silva GP; Castro RB; Ferreira B; Barreto DM; Frota AC; Hofer CB; Milagres LG
    Vaccine; 2016 Dec; 34(50):6116-6119. PubMed ID: 27847176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Heron L; Lambert S; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2011 Apr; 30(4):340-2. PubMed ID: 21068692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
    de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
    Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination.
    Wing JB; Smart L; Borrow R; Findlow J; Findlow H; Heath AW; Read RC
    Clin Infect Dis; 2011 Jun; 52(11):1317-23. PubMed ID: 21596673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of meningococcal serogroup C vaccine programmes.
    Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
    Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children.
    Joseph H; Ryall R; Bybel M; Papa T; MacLennan J; Buttery J; Borrow R
    J Infect Dis; 2003 Apr; 187(7):1142-6. PubMed ID: 12660929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.
    de Voer RM; Mollema L; Schepp RM; de Greeff SC; van Gageldonk PG; de Melker HE; Sanders EA; Berbers GA; van der Klis FR
    PLoS One; 2010 Aug; 5(8):e12144. PubMed ID: 20730091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.
    Campbell JD; Edelman R; King JC; Papa T; Ryall R; Rennels MB
    J Infect Dis; 2002 Dec; 186(12):1848-51. PubMed ID: 12447774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
    Pollard AJ; Green C; Sadarangani M; Snape MD
    Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
    [No Abstract]   [Full Text] [Related]  

  • 39. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine.
    Richmond P; Kaczmarski E; Borrow R; Findlow J; Clark S; McCann R; Hill J; Barker M; Miller E
    J Infect Dis; 2000 Feb; 181(2):761-4. PubMed ID: 10669372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
    Ostergaard L; Lebacq E; Poolman J; Maechler G; Boutriau D
    Vaccine; 2009 Jan; 27(1):161-8. PubMed ID: 18834910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.